What is the Buying Price of Cohance Lifesciences Share?

The Buying Price of Cohance Lifesciences share is 428.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

How to buy Cohance Lifesciences Share at Choice?

To buy Cohance Lifesciences stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Cohance Lifesciences, choose your preferred order type, and place the trade.

What is the PE ratio of Cohance Lifesciences Shares?

The Price-to-earnings (P/E) ratio of Cohance Lifesciences shares is 91.66. You can compare it with the sector average for relative valuation.

What is the PB ratio of Cohance Lifesciences Shares?

The Price to Book (P/B) ratio Cohance Lifesciences shares is 4.2. Useful to assess the stock's value relative to its book value.

Is Cohance Lifesciences Overvalued?

To assess Cohance Lifesciences’s valuation compare Sector P/E, P/B which are 69.94 & 2.97 with sector averages, along with growth rates and financial metrics.

What is the Market Cap of Cohance Lifesciences?

The Market Cap of Cohance Lifesciences is 16408.30 CR. It indicates the company's size category and trading liquidity.

What is the 52 Week High and Low of Cohance Lifesciences Share Price?

The 52 week high and low prices of Cohance Lifesciences share price is 1121.15 & 266.7. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Which sector does Cohance Lifesciences belong to?

Cohance Lifesciences belongs to the Healthcare sector.

Cohance Lifesciences Share price

COHANCE

Healthcare Large Cap

428.9

0.50 (-0.12%)

NSE

BSE

Last updated on 2 Jun, 2026 | 15:31 IST

BUYSELL

Today's High

430.55

Today's Low

424.10

52 Week Low

266.70

52 Week High

1121.15

Free Demat with Zero AMC*

Cohance Lifesciences Chart

ChartIQ

TradingView

Cohance Lifesciences Share Key Metrics

Volume

2.80 L

Market Cap

16408.30 CR

LTQ@LTP

1@428.90

ATP

427.49 Var Margin

100 %

Circuit Range

343.55-515.25

Delivery %

35.46 %

Value

11.98 CR

ASM/GSM

No

Market Lot

1

Summary

2 Jun, 2026 | 15:31 को, Cohance Lifesciences का शेयर प्राइस आज ₹428.9 पर है, जो दिन के लिए 0.50% की -0.12 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹424.10 और ₹430.55 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹266.70 से ₹1121.15 तक रही है। ट्रेडिंग गतिविधि के मामले में, Cohance Lifesciences ने 280245 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹382567140 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹42749 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 1,42890 रही। यह स्टॉक ₹343.55-515.25 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹11.98 CR है। दिन के लिए डिलीवरी परसेंटेज 35.46% रही। इसके अतिरिक्त, Cohance Lifesciences वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Cohance Lifesciences Fundamentals

P/E Ratio

91.66

P/B Ratio

4.2

Div. Yield

0

Sector P/E

69.94

Sector P/B

2.97

Sec. Div. Yield

0.55

Cohance Lifesciences Resistance and Support

Pivot 433.6

Resistance

First Resistance

440.1

Second Resistance

450.8

Third Resistance

457.3

Support

First Support

422.9

Second Support

416.4

Third Support

405.7

Cohance Lifesciences Shareholding Pattern

2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

57.49%

Mutual Fund

18.57%

Insurance

3.13%

Foreign Institutional Investors

5.59%

Domestic Institutional Investors

0.1%

Retail

15.12%

Others

0%

Total Promoters

MAR '26

57.49%

Cohance Lifesciences Corporate Actions

Date	Agenda
2026-05-12	Audited Results
2026-02-12	Quarterly Results

Cohance Lifesciences News

Cohance Lifesciences Limited

Cohance Lifesciences released the transcript of its Q4 & FY26 earnings conference call. The company reported FY26 revenue of INR 22.68 billion, impacted by destocking and inventory adjustments. Management expects recovery to begin from H2 FY27 onwards.

May 15 2026 20:54:39

Cohance Lifesciences Limited

Cohance Lifesciences shareholders to vote on the appointment of Mr. Umang Vohra as Chairman and Group CEO, with an effective date of May 2026. The postal ballot also includes a special resolution for his remuneration, which exceeds prescribed limits, and approval for new Employee Stock Option Plans, including grants potentially exceeding 1% of issued capital.

May 14 2026 20:14:13

Cohance Lifesciences Limited

Cohance Lifesciences issued a postal ballot notice for shareholder approval of key items including the appointment of Mr. Umang Vohra as Chairman & Group CEO and a new Employee Stock Option Plan (ESOP 2026) involving 6.25% of fully diluted shares. The e-voting period is from May 15 to June 13, 2026.

May 14 2026 18:11:10

Cohance Lifesciences Ltd - 543064 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Cohance Lifesciences launched a postal ballot for shareholders to approve the appointment of Mr. Umang Vohra as Chairman & Group CEO, effective May 2026. The ballot also includes his remuneration package, valued at USD 4.7 million annually, and the new Employee Stock Option Plan 2026 (ESOP 2026) which will result in a 7.75% capital dilution over 7.5 years. E-voting is scheduled from May 15 to June 13, 2026.

May 14 2026 18:11:03

Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4

Cohance Lifesciences shares slipped by 7% after Jefferies downgraded the stock from 'Buy' to 'Hold' and reduced its target price, citing a weak fourth-quarter outlook.

May 13 2026 10:10:27

Q4 Results Highlights: Texmaco Rail profit at ₹57.7 crore; Cohance Lifesciences profit at ₹20 crore

Cohance Lifesciences is scheduled to announce its financial results for the fourth quarter of fiscal year 2026 on May 12, 2026, alongside several other companies as the earnings season progresses. [1, 2, 4]

May 12 2026 22:13:14

Cohance Lifesciences Ltd - 543064 - Board Meeting Outcome for Outcome Of The Board Meeting

Cohance Lifesciences reported FY26 consolidated revenue of ₹22.69 bn (down 13% YoY) and net profit of ₹1.84 bn (down 65.4% YoY). The Q4 consolidated revenue declined 26.3% YoY to ₹6.19 bn, with net profit falling 76.5% YoY to ₹0.33 bn, influenced by inventory adjustments and pricing pressures. The Board also revised its KMP materiality policy.

May 12 2026 17:39:38

Cohance Lifesciences Limited

Cohance Lifesciences board will meet on May 12, 2026, to consider and approve the yearly audited standalone and consolidated financial results for the period ended March 2026. This meeting will finalize the company's financial performance for the full fiscal year.

May 06 2026 15:10:36

Cohance Lifesciences Ltd - 543064 - Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company, For The Quarter And Financial Year Ended March 31, 2026.

Cohance Lifesciences board is scheduled to meet on May 12, 2026, to consider and approve its audited financial results for the quarter and full financial year ended March 31, 2026. This meeting will review both standalone and consolidated financials.

May 06 2026 15:05:00

Name	Position
Vivek Sharma	Chairman
Umang Vohra	Additional Director

Cohance Lifesciences Similar Stocks

Onesource Specialty Pharma Ltd.

1828.60

-9.20 (0.50%)

Eris Lifesciences Ltd.

1362.10

-16.30 (1.18%)

Granules India Ltd.

777.55

-1.45 (0.19%)

Astrazeneca Pharma India Ltd.

8710.00

-19.00 (0.22%)

Natco Pharma Ltd.

939.30

6.00 (0.64%)

Jubilant Pharmova Ltd.

975.05

-12.50 (1.27%)

Caplin Point Laboratories Ltd.

1988.10

-10.80 (0.54%)

Dr. Agarwal's Health Care Ltd.

476.55

-4.80 (1.00%)

Alembic Pharmaceuticals Ltd.

725.50

5.50 (0.76%)

Rainbow Children's Medicare Ltd.

1341.40

-28.20 (2.06%)

Cohance Lifesciences FAQs

Cohance Lifesciences शेयर का खरीद मूल्य 428.9 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Cohance Lifesciences शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Cohance Lifesciences शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 91.66 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Cohance Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.2 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Cohance Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.97 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Cohance Lifesciences का मार्केट कैप 16408.30 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Cohance Lifesciences शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1121.15 और 266.70 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।